Your Health, We Care
Release date: 2026-01-29 11:40:39 Recommended: 8
Revumenib (Revuforj) is an oral, first-in-class targeted Menin protein inhibitor indicated for the treatment of relapsed or refractory acute leukemia with specific genetic abnormalities (KMT2A rearrangement or NPM1 mutation).
The effects and recommendations for concomitant use of other drugs with revumenib are as follows:
Effect: Increases the systemic exposure of revumenib, which may raise the risk of adverse reactions.
Measure: If concomitant use is necessary, the dose of revumenib should be reduced.
Effect: May decrease the systemic exposure of revumenib and increase that of its M1 metabolite, which could reduce the efficacy of revumenib or elevate the risk of QT prolongation associated with the M1 metabolite.
Measure: Concomitant use with revumenib should be avoided.
Effect: May induce QTc interval prolongation and its associated adverse reactions.
Measure: Concomitant use with revumenib should be avoided.
The above recommendations are based on the risk assessment of drug-drug interactions and are intended to ensure medication safety and efficacy.
Revumenib should be taken on an empty stomach or with a low-fat meal (containing approximately 400 calories and no more than 25% fat).
There are no known interactions between revumenib and alcohol, but heavy alcohol consumption may slow down the immune response and make it more difficult for the body to fight cancer.
More frequent electrocardiographic monitoring may be required for patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or those taking known QTc interval-prolonging drugs.
Initiation of revumenib is contraindicated in patients with a QTcF > 450 milliseconds.
Correct electrolyte abnormalities, including hypokalemia and hypomagnesemia, before and during revumenib treatment.
Patients are advised to consult a doctor immediately if they experience dizziness, loss of consciousness, or signs of cardiac arrhythmia. Patients with a history of hypokalemia or hypomagnesemia should be advised of the importance of electrolyte monitoring.
